Arabic Arabic English English French French German German
dark

Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021

Landos Biopharma, Inc. announced that data from the Phase 2 clinical trial of omilancor in ulcerative colitis has been accepted for oral presentation at the upcoming United European Gastroenterology Week 2021. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Hyperoside ameliorates periodontitis.

Next Post

Beyond telehealth – new data-driven solutions for better care

Related Posts
Total
0
Share